Approximately 50% of patients with newly diagnosed sarcoma eventually die of disease. The purpose of the Developmental Research Program of the MSKCC SPORE in Soft Tissue Sarcoma is to support innovative translational research projects in sarcoma. The translational research projects in this program aim to use knowledge of animal and human sarcoma biology to develop and test interventions related to improving diagnosis, prognosis, and treatment of pafients with soft fissue sarcoma. This program will allow us to respond quickly to new opportunifies in translational research and will help us recruit new scientific talent into our SPORE and, more broadly, into sarcomarelevant research.
The specific aims of the Developmental Research Program are: 1) to provide seed funding for innovative, investigator-initiated research in the biology, pathogenesis, progression, and natural history of sarcoma, 2) to fund research with exceptional potential to advance the translational research goals of the SPORE, and 3) to establish a mechanism for strategic interactions with other SPOREs and other major national and international research centers. We are budgeting $450,000 yeariy for this program including $50,000 from the SPORE award itself and $400,000 in MSKCC institutional funds. The priority for funding will be those inifiafives considered most creafive and of the highest scientific quality. Preference will be given to projects that complement the long-term research goals of the SPORE and advance our translational research objecfives. The executive committee can also solicit and fund experimental or clinical initiatives that address an urgent and specific need in the MSKCC SPORE in Soft Tissue Sarcoma program or a unique research opportunity. The internal scientific advisory committee, under the chairmanship of Murray F. Brennan, MD, will review applications to determine priorities for use of these funds and will annually select projects for one to two years of funding. The projects that appear most promising after two years of funding will be considered for incorporation into the SPORE as Research Projects, either in current or future funding cycles.
|Tap, William D; Jones, Robin L; Van Tine, Brian A et al. (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388:488-97|
|Argani, Pedram; Reuter, Victor E; Zhang, Lei et al. (2016) TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity. Am J Surg Pathol 40:1484-1495|
|Specht, Katja; Zhang, Lei; Sung, Yun-Shao et al. (2016) Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40:433-42|
|Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2016) BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities. Am J Surg Pathol 40:1670-1678|
|McFadden, David G; Politi, Katerina; Bhutkar, Arjun et al. (2016) Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A 113:E6409-E6417|
|Patwardhan, Parag P; Ivy, Kathryn S; Musi, Elgilda et al. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 7:4093-109|
|Leduc, Charles; Zhang, Lei; Ã–z, Buge et al. (2016) Thoracic Myoepithelial Tumors: A Pathologic and Molecular Study of 8 Cases With Review of the Literature. Am J Surg Pathol 40:212-23|
|Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2016) Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy: Overlapping Genetic Features With Clear Cell Sarcoma of Kidney. Am J Surg Pathol 40:1009-20|
|Moore, Amanda R; Ceraudo, Emilie; Sher, Jessica J et al. (2016) Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48:675-80|
|Huang, Shih-Chiang; Alaggio, Rita; Sung, Yun-Shao et al. (2016) Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma. Am J Surg Pathol 40:876-85|
Showing the most recent 10 out of 108 publications